Table 2 Objective response determined by RECIST v1.1
Gastric cancer (n=35) | Hepatocellular carcinoma (n=21) | Biliary tract cancer (n=13) | Urothelial carcinoma (n=12) | Head and neck squamous cell carcinoma (n=10) | Renal cell carcinoma (n=10) | Pancreatic cancer (n=10) | Esophageal cancer (n=10) | |
|---|---|---|---|---|---|---|---|---|
Best overall response | ||||||||
Complete response | 1 (3%) | 0 | 0 | 1 (8 %) | 0 | 0 | 0 | 0 |
Partial response | 6 (17 %) | 1 (5%) | 1 (8%) | 1 (8%) | 2 (20%) | 2 (20%) | 0 | 0 |
Stable disease | 6 (17%) | 6 (29%) | 1 (8%) | 1 (8%) | 4 (40%) | 1 (10%) | 2 (20%) | 3 (30%) |
Progressive disease | 19 (54%) | 11 (52%) | 9 (69%) | 6 (50%) | 2 (20%) | 5 (50%) | 8 (80%) | 4 (40%) |
Not evaluable | 3 (9%) | 3 (14%) | 2 (15%) | 3 (25%) | 2 (20%) | 2 (20%) | 0 | 3 (30%) |
Objective response rate | 20.0% (8.4–36.9) | 4.8% (0.1–23.8) | 7.7% (0.2–36.0) | 16.7% (2.1–48.4) | 20.0% (2.5–55.6) | 20.0% (2.5–55.6) | 0% (0–30.9) | 0% (0–30.9) |
Disease control rate | 37.1% (21.5–55.1) | 33.3% (14.6–57.0) | 15.4% (1.9–45.5) | 25.0% (5.5–57.2) | 60.0% (26.2–87.8) | 30.0% (6.7–65.3) | 20.0% (2.5–55.6) | 30.0% (6.7–65.3) |
Clinical benefit rate | 28.6% (14.6–46.3) | 9.5% (1.2–30.4) | 7.7% (0.2–36.0) | 16.7% (2.1–48.4) | 30.0% (6.7–65.3) | 30.0% (6.7–65.3) | 0% (0–30.9) | 10.0% (0.3–44.5) |